Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on June 17, 2019, to report a significant clinical milestone. The company is a biopharmaceutical firm focused on developing plant cell-expressed recombinant proteins.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the completion of patient enrollment in the Phase III BRIGHT clinical trial for pegunigalsidase alfa (PRX-102). This drug candidate is designed for the treatment of Fabry disease via intravenous infusions of 2 mg/kg administered every 4 weeks.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the enrollment completion. No specific financial guidance, future outlook, management commentary on financial performance, or discussion of risks and contingencies is included in the text of this 8-K.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the BRIGHT trial design and next steps.
- Review the company's most recent 10-Q or 10-K filing for current financial status, cash runway, and liquidity.
- Monitor upcoming announcements regarding the primary endpoint analysis of the Phase III BRIGHT trial.
- Confirm the regulatory status of PRX-102 with the FDA or EMA.